Astellas UK has been suspended from the Association of the British Pharaceutial Industry over a serious breach of the groups code of practice (for its behaviour in marketing a cancer drug) according to a report in the Sunday Telegraph.
Is this likely to affect the supply or availability of Prograf which they also market? I suspect it will not have an affect but would be interested in views more informed than mine.